» Articles » PMID: 36551500

The Blood-Brain Barrier and Pharmacokinetic/Pharmacodynamic Optimization of Antibiotics for the Treatment of Central Nervous System Infections in Adults

Overview
Specialty Pharmacology
Date 2022 Dec 23
PMID 36551500
Authors
Affiliations
Soon will be listed here.
Abstract

Bacterial central nervous system (CNS) infections are serious and carry significant morbidity and mortality. They encompass many syndromes, the most common being meningitis, which may occur spontaneously or as a consequence of neurosurgical procedures. Many classes of antimicrobials are in clinical use for therapy of CNS infections, some with established roles and indications, others with experimental reporting based on case studies or small series. This review delves into the specifics of the commonly utilized antibacterial agents, updating their therapeutic use in CNS infections from the pharmacokinetic and pharmacodynamic perspectives, with a focus on the optimization of dosing and route of administration that have been described to achieve good clinical outcomes. We also provide a concise synopsis regarding the most focused, clinically relevant information as pertains to each class and subclass of antimicrobial therapeutics. CNS infection morbidity and mortality remain high, and aggressive management is critical in ensuring favorable patient outcomes while averting toxicity and upholding patient safety.

Citing Articles

Enhancing antibiotic therapy through comprehensive pharmacokinetic/pharmacodynamic principles.

Alikhani M, Nazari M, Hatamkhani S Front Cell Infect Microbiol. 2025; 15:1521091.

PMID: 40070375 PMC: 11893874. DOI: 10.3389/fcimb.2025.1521091.


Pharmacometabolomics in TB meningitis-Understanding the pharmacokinetic, metabolic, and immune factors associated with anti-TB drug concentrations in cerebrospinal fluid.

Collins J, Kipiani M, Jin Y, Sharma A, Tomalka J, Avaliani T PLoS One. 2025; 20(3):e0315999.

PMID: 40029856 PMC: 11875335. DOI: 10.1371/journal.pone.0315999.


Cerebrospinal fluid proteomics reveals the innate immunity and blood-brain barrier dysregulation in a patient with multidrug-resistant ventriculitis treated with intrathecal and intravenous polymyxin B.

Li M, Liu D, Bergen P, Liang S, Chen J, Kho Z Heliyon. 2025; 10(24):e40893.

PMID: 39759273 PMC: 11699078. DOI: 10.1016/j.heliyon.2024.e40893.


Antibiotic Use and Subsequent Cognitive Decline and Dementia Risk in Healthy Older Adults.

Wang Y, Zhou Z, Broder J, Woods R, Orchard S, Wolfe R Neurology. 2024; 104(1):e210129.

PMID: 39693592 PMC: 11655135. DOI: 10.1212/WNL.0000000000210129.


Antibiotic-induced neuropsychiatric toxicity: epidemiology, mechanisms and management strategies - a narrative literature review.

Althubyani A, Canto S, Pham H, Holger D, Rey J Drugs Context. 2024; 13.

PMID: 39072301 PMC: 11281100. DOI: 10.7573/dic.2024-3-3.


References
1.
Nau R, Seele J, Djukic M, Eiffert H . Pharmacokinetics and pharmacodynamics of antibiotics in central nervous system infections. Curr Opin Infect Dis. 2018; 31(1):57-68. DOI: 10.1097/QCO.0000000000000418. View

2.
Burgess D, Frei C, Lewis Ii J, Fiebelkorn K, Jorgensen J . The contribution of pharmacokinetic-pharmacodynamic modelling with Monte Carlo simulation to the development of susceptibility breakpoints for Neisseria meningitidis. Clin Microbiol Infect. 2006; 13(1):33-9. DOI: 10.1111/j.1469-0691.2006.01617.x. View

3.
Farmakiotis D, Zeluff B . IMAGES IN CLINICAL MEDICINE. Metronidazole-Associated Encephalopathy. N Engl J Med. 2016; 374(15):1465. DOI: 10.1056/NEJMicm1505174. View

4.
Rybak M, Albrecht L, Boike S, Chandrasekar P . Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother. 1990; 25(4):679-87. DOI: 10.1093/jac/25.4.679. View

5.
Pollay M . Transport mechanisms in the choroid plexus. Fed Proc. 1974; 33(9):2064-9. View